Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Operating Expenses: 2012-2025

Historic Operating Expenses for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to $33.5 million.

  • Enanta Pharmaceuticals' Operating Expenses fell 24.63% to $33.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $150.7 million, marking a year-over-year decrease of 20.42%. This contributed to the annual value of $150.7 million for FY2025, which is 20.42% down from last year.
  • As of Q3 2025, Enanta Pharmaceuticals' Operating Expenses stood at $33.5 million, which was down 9.93% from $37.2 million recorded in Q2 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Operating Expenses peaked at $58.1 million during Q4 2021, and registered a low of $33.5 million during Q3 2025.
  • Its 3-year average for Operating Expenses is $45.7 million, with a median of $44.5 million in 2024.
  • In the last 5 years, Enanta Pharmaceuticals' Operating Expenses soared by 33.65% in 2021 and then dropped by 24.63% in 2025.
  • Quarterly analysis of 5 years shows Enanta Pharmaceuticals' Operating Expenses stood at $58.1 million in 2021, then decreased by 7.68% to $53.6 million in 2022, then fell by 1.32% to $52.9 million in 2023, then fell by 23.42% to $40.5 million in 2024, then decreased by 24.63% to $33.5 million in 2025.
  • Its Operating Expenses was $33.5 million in Q3 2025, compared to $37.2 million in Q2 2025 and $39.5 million in Q1 2025.